About Gentronix
Gentronix is a company based in Alderley Edge (United Kingdom) founded in 1999 was acquired by Scantox in September 2024.. Gentronix has raised $3.84 million across 3 funding rounds from investors including Mercia, Scantox and NVM Private Equity. The company has 1 employees as of December 31, 2015. Gentronix offers products and services including Genetic Toxicology Testing, GLP Genotoxicity Services, Skin Toxicology Services, and Flow Cytometry Services. Gentronix operates in a competitive market with competitors including Jade Bioscience, Tigermed, Shanghai Yaocheng Health Technology, ReveraGen and Aquila BioMedical, among others.
- Headquarter Alderley Edge, United Kingdom
- Employees 1 as on 31 Dec, 2015
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Gentronix Limited
- Date of Incorporation 15 Jul, 1999
- Jurisdiction ALDERLEY EDGE, CHESHIRE, ENGLAND
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gentronix
Gentronix offers a comprehensive portfolio of products and services, including Genetic Toxicology Testing, GLP Genotoxicity Services, Skin Toxicology Services, and Flow Cytometry Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Screens for genotoxic hazards in chemicals using rapid assays.
Conducts GLP-compliant studies for gene mutation and safety.
Assesses skin irritation and sensitisation potential in vitro.
Delivers endpoints for toxicological hazard identification.
Unlock access to complete
Unlock access to complete
Funding Insights of Gentronix
Gentronix has successfully raised a total of $3.84M across 3 strategic funding rounds. The most recent funding activity was a Unspecified round of $938.37 thousand completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Unspecified — $938,374
-
First Round
First Round
(07 Mar 2007)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2021 | Amount | Unspecified - Gentronix | Valuation | NVM |
|
| Jan, 2020 | Amount | Unspecified - Gentronix | Valuation | Mercia |
|
| Mar, 2007 | Amount | Unspecified - Gentronix | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Gentronix
Gentronix has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia, Scantox and NVM Private Equity. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are managed across the UK.
|
Founded Year | Domain | Location | |
|
Investment management services are provided by Mercia to various clients.
|
Founded Year | Domain | Location | |
|
Laboratory focused on providing pharmacology, toxicology, and histopathology services
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Gentronix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Gentronix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Gentronix Comparisons
Competitors of Gentronix
Gentronix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jade Bioscience, Tigermed, Shanghai Yaocheng Health Technology, ReveraGen and Aquila BioMedical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provides toxicology, chemistry, and consultancy services for agrochemical industries.
|
|
| domain | founded_year | HQ Location |
Drug development and preclinical services are provided by Tigermed.
|
|
| domain | founded_year | HQ Location |
Clinical trial services to biopharma sector are provided.
|
|
| domain | founded_year | HQ Location |
Steroids for Duchenne muscular dystrophy treatment are developed.
|
|
| domain | founded_year | HQ Location |
Preclinical services in immunology, regeneration, neuroscience, and histology are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Gentronix
Frequently Asked Questions about Gentronix
When was Gentronix founded?
Gentronix was founded in 1999 and raised its 1st funding round 8 years after it was founded.
Where is Gentronix located?
Gentronix is headquartered in Alderley Edge, United Kingdom. It is registered at Alderley Edge, Cheshire, United Kingdom.
Is Gentronix a funded company?
Gentronix is a funded company, having raised a total of $3.84M across 3 funding rounds to date. The company's 1st funding round was a Unspecified of $1.93M, raised on Mar 07, 2007.
How many employees does Gentronix have?
As of Dec 31, 2015, the latest employee count at Gentronix is 1.
What does Gentronix do?
Gentronix provides services and solutions to help organisations optimise the development of drugs and other chemicals, by reducing attrition due to toxicity thus ensuring safer products across a wide range of chemistry driven industries. Provide contract services for genotoxicity using patented human cell GADD45a reporter, GreenScreen HC and BlueScreen HC assays and related assays including Micronucleus and Ames MPF. Offerings include - GreenScreen HC, BlueScreen HC, Ames MPF, Ames bacterial reverse mutation assay (OECD 471 ), In Vitro Mammalian Cell Micronucleus Test (OECD 487), MicroFlow Micronucleus Test, Micronucleus Test in vivo, Comet Assay, H2AX by Flow Cytometry, Apoptosis Suite, Flow Cytometry Services and Predictive Toxicology Services. Serves - Pharmaceutical Industry, Chemical Industry, Agrochemical, Fragrances and Flavours, Personal Care Products, Consumer Products, Biomaterials, Biomedical Devices and Contract Research Organisations.
Who are the top competitors of Gentronix?
Gentronix's top competitors include PHAXIAM, BioQual and Jade Bioscience.
What products or services does Gentronix offer?
Gentronix offers Genetic Toxicology Testing, GLP Genotoxicity Services, Skin Toxicology Services, and Flow Cytometry Services.
Who are Gentronix's investors?
Gentronix has 3 investors. Key investors include Mercia, Scantox, and NVM Private Equity.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.